Strategic Expansion Mergers and acquisitions activity in glaucoma treatment capacity, highlighted by the December 2024 Elios Vision acquisition, presents a sales opening for Bausch + Lomb Surgical to offer upgraded intraocular devices, glaucoma management solutions, or complementary tools to integrate with the newly expanded glaucoma care footprint.

European Market Focus Active European launches such as Pure-Line gases reported at Euretina 2023 indicate a focus on advanced surgical consumables; leverage this momentum to position compatible gas delivery systems, sterilization solutions, and service packages to ophthalmology centers adopting these products.

Technology Enablement The tech stack shows a digital-forward patient and provider engagement approach; opportunities exist to upsell digital training platforms, surgical planning software add-ons, or data analytics services that complement operating room solutions and post‑op outcomes tracking.

Clinical Leadership With a long-standing heritage and a mission to empower surgeons, there is potential to partner on education programs, certification courses, and surgeon advisory boards to drive adoption of new surgical devices and exclusive product lines.

Growth and Investment Revenue scale places the company in the mid‑market range; target mid‑sized ophthalmology groups and regional chains in Europe for bundled equipment upgrades, service contracts, and volume-based pricing to expand share with sustainability-minded procurement teams.